A carregar...
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
ALK-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of ALK inhibitors. Thus, it is imperative for clinicians to screen appropriate patients for this driver mutation with a molecular testing platform capable of ca...
Na minha lista:
| Publicado no: | Lung Cancer (Auckl) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6234987/ https://ncbi.nlm.nih.gov/pubmed/30519133 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S186804 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|